Matteo Colombo/DigitalVision via Getty Images Topline Summary and Update Arcus Biosciences, Inc. (NYSE:RCUS) is a cancer-focused biotech I've covered a few times with relative optimism, and as an investment thesis, it has yet to pay off. However, with an important trial update at this year's ASCO Annual Meeting and a number of important upcoming catalysts, I'm inclined to remain upbeat about the company's outlook, despite the more recent setbacks faced by the TIGIT story. Let's take another look. Pipeline U ...